Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

2109 - Analysis of various prognostic factors on local control and survival in post operative cases of malignant salivary gland tumors (580P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Mallupattu Kumar

Citation

Annals of Oncology (2017) 28 (suppl_10): x177-x182. 10.1093/annonc/mdx668

Authors

M. Kumar, H. Manchala, S. Kumari, S. R

Author affiliations

  • Radiation Oncology, MNJ INSTITUTE OF ONCOLOGY, 500034 - hyderabad/IN
More

Resources

Abstract 2109

Background

The role of adjuvant therapy has not been clearly defined in certain subroups of salivary gland tumors. Elective LN irradiation has been the subject of debate. Our study analysed various prognostic factors and the role of adjuvant radiotherapy in salivary gland tumors on local control rate and median survival.

Methods

We analysed the data of 84 patients of malignant salivary gland tumors from 2010 to 2015 who underwent primary surgery at out institute with median follow up of 32 months range (3-84 months) using inclusion and exclusion criteria. None of the patients received adjuvant/concurrent chemotherapy in our study. The role of various factors like type of surgery (conservative/radical), grade of tumor, histology, PNI, margin+, LVSI+, adjuvant RT, Elective LN irradiation, LN dissection and size of primary tumor on two year local recurrence rate was evaluated as primary end point. Median survival was our secondary endpoint. Local reactions were evaluated using RTOG criteria. Stastical analysis was done using SPSS version 22.0

Results

Table: 580P

GenderMEDIAN- 4O YRS RANGE- 8- 74 YRS
SexMALE- 38% (n = 32) FEMALES- 72% (n = 52)
SitePAROTID-92.9% (n = 8) SUBMANDIBULAR-4.8 (n = 4) MINOR SALIVARY GLAND-2.4% (n = 2)
SurgeryCONSERVATIVE- 81% (n = 68) RADICAL- 19% (n = 16)
HistologyMUCOEPIDERMOID- 50% (n = 42) ADENOID CYSTIC CA -16.7% (n = 14) ACNIC CELL CA.- 7.1% (n = 6) SQUAMOUS CELL CA- 4.8% (n = 4) SARCOMA- 4.8% (n = 4) MALGNT. EX PLEOMORPHIC ADENOMA-2.4% (n = 2)
LN dissection43% (n = 36)
pLN+7% (n = 6)
Tumor size >4 CMS52% (n = 44)
GRADEHIGH-48% (n = 40) INTERMEDIATE-14% (n = 12) LOW-38% (n = 32)
LVSI+2.5% (n = 3)
Margin+7% (n = 6)
PNI+7% (n = 6)
Adjuvant RT72% (n = 52)
Elective LNI38%(n = 32)
RT doseMEDIAN- 55 Gy RANGE- 50 -66 Gy
2 yr LC rate69% (n = 58)
METS+17% (n = 14)

2 yr local control (LC) in patients who received adj RT is 88.5% and it is 37.5% who didn't receive adj RT which is statistically significant (p 4 cm and LN + have shown a trend to decrease LC rate but are not statistically significant. Interestingly, patients with LN dissection have trend towards decreased LC rate, probably due to more conservative/less aggressive LN dissection in patients who are clinically LN+. Patients with elective LN irradiation (ELNI) have a better 2 yr LC rate in high grade and large tumors than low grade and small tumors (70% vs 41%, p=.04, 64% vs 30%, p = 0.03 respectively). Adj RT doses of more than 60 Gy does not seem to improve LC in adjuvant setting and statistically not significant. The expected median survival in adj RT is 47 months vs 40 months for surgery alone (p = 0.14). Grade II reactions are 79% and 84% for xerostomia and dermatitis.

Conclusions

Adjuvant RT improves local control with trend towards improvement in survival. ELNI in high grade and large tumors is beneficial.

Clinical trial identification

Legal entity responsible for the study

MNJ Institute of Oncology, Hyderabad, India

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings